Startup | August 13, 2024
HealthCRED secures US$ 1.2 million in seed funding
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
Morepen Labs successfully raised Rs. 200 Crore through QIP
Revolutionary technology will further boost OneSource’s scientific services offerings
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
The state-of-the-art facility is equipped with best-in-class equipment and control systems
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Subscribe To Our Newsletter & Stay Updated
